Harrow said first-quarter results were weighed down by a discrete revenue issue tied to VEVYE coverage and high-deductible patients. Management stressed that underlying demand for its core ophthalmic products is accelerating, suggesting the shortfall may be temporary rather than structural.
Harrow said first-quarter results were weighed down by a discrete revenue issue tied to VEVYE coverage and high-deductible patients. Management stressed that underlying demand for its core ophthalmic products is accelerating, suggesting the shortfall may be temporary rather than structural.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
